EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial

Sitagliptin, ein DPP-4-Inhibitor, fördert die Heilung des diabetischen Fußulkus: eine randomisierte kontrollierte Studie

Wei Gao, Dawei Chen, Hua He, Nenggang Jiang, Lihong Chen, Xingwu Ran iD

Journal of Diabetes · 2025-09 · 17 (9)

DOI: 10.1111/1753-0407.70156 ↗

Auf einen Blick

In einer randomisierten Studie heilte das diabetische Fußulkus unter Sitagliptin zusätzlich zur Standardtherapie besser als unter Standardtherapie allein. Es traten keine sitagliptinassoziierten unerwünschten Ereignisse auf.

Fragestellung

Wirkt Sitagliptin bei diabetischen Fußulzera zusätzlich zur Standardtherapie auf die Ulkusheilung?

Methode

Randomisierte, offene klinische Studie; 62 Teilnehmende, je 31 pro Gruppe; Sitagliptin 100 mg 1-mal täglich plus Standardtherapie vs. Standardtherapie allein.

Ergebnisse

62 Teilnehmende, 31 pro Gruppe; 1 Verlust pro Gruppe. Unter Sitagliptin stärkere Ulkusflächenreduktion und bessere Heilung (p < 0,05), mehr CD34+ EPCs und höhere SDF-1α-Werte (je p < 0,05); HbA1c ohne Unterschied.

Schlussfolgerung der Autor:innen

Sitagliptin könnte die Heilung diabetischer Fußulzera unabhängig von der Glukosesenkung fördern, möglicherweise über mehr CD34+ EPCs im peripheren Blut.

Kernaussagen

  • Bessere Ulkusheilung unter Sitagliptin als unter Standardtherapie
  • Mehr CD34+ EPCs und höhere SDF-1α-Werte unter Sitagliptin
  • Keine sitagliptinassoziierten unerwünschten Ereignisse berichtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes, online erschienen am 15.09.2025. Verfasst von Wei Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors, Diabetic Foot, Wound Healing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Bureau of Sichuan Province, Health Commission of Sichuan Province, 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This randomized controlled trial (RCT) was designed to evaluate the effects of sitagliptin on diabetic foot ulcers (DFUs).

Methods

This was a randomized, open‐label clinical trial. The participants were assigned to either the control group, which received standard conventional therapy alone, or the sitagliptin treatment group, which received an oral administration of sitagliptin (100 mg once daily) in conjunction with standard conventional therapy. The primary endpoints were the ulcer healing rate and adverse reactions. The secondary endpoints included the time to ulcer healing, peripheral blood CD34+ endothelial progenitor cells (EPCs) count, serum levels of stromal cell‐derived factor‐1α (SDF‐1α), and glycosylated hemoglobin A1c (HbA1c).

Results

A total of 62 subjects were enrolled in this trial, with 31 individuals assigned to each group. One participant from each group was lost to follow‐up. Posttrial analysis revealed that, compared with the control group, the sitagliptin group demonstrated a significantly greater reduction in ulcer area and improved efficacy in terms of ulcer healing ( p < 0.05). Although not statistically significant ( p = 0.071), the sitagliptin group also tended to have a shorter ulcer healing time. Additionally, the sitagliptin group presented significantly greater numbers of CD34+ EPCs and higher SDF‐1α levels compared to the control group ( p < 0.05). No statistically significant difference in HbA1c levels was observed between the two groups ( p > 0.05). No adverse events associated with sitagliptin treatment were reported.

Conclusions

The DPP‐4 inhibitor sitagliptin may facilitate the healing of DFUs independent of its glucose‐lowering effects, potentially by enhancing the mobilization of CD34 + EPCs in peripheral blood. Trial Registration: Registration number: ChiCTR 2000029230, Approval date: 2020/01/19

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsDiabetic FootWound HealingDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedAgedGlycated HemoglobinChemokine CXCL12Treatment OutcomeEndothelial Progenitor Cells

Stichwörter der Autor:innen

diabetic foot ulcerdipeptidyl peptidase‐4 (DPP‐4) inhibitorsrandomized controlled trial (RCT)sitagliptintherapy

Substanzen

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinChemokine CXCL12

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
  • Health Management Center, General Practice Center, West China Hospital, Chengdu, China.
  • Innovation Research Center for Diabetic Foot, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Endocrinology and Metabolism, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China.
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xingwu Ran

Förderung

  • Science and Technology Bureau of Sichuan Province
  • Health Commission of Sichuan Province
  • 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University
  • 1.3.5 Project of Center for High Altitude Medicine, West China Hospital, Sichuan University

Zitieren

APA

Gao, W., Chen, D., He, H., Jiang, N., Chen, L., & Ran, X. (2025). Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. Journal of Diabetes, 17(9). https://doi.org/10.1111/1753-0407.70156

Vancouver

Gao W, Chen D, He H, Jiang N, Chen L, Ran X. Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. Journal of Diabetes. 2025;17(9). doi:10.1111/1753-0407.70156

BibTeX
@article{Gao2025,
  author = {Gao, Wei and Chen, Dawei and He, Hua and Jiang, Nenggang and Chen, Lihong and Ran, Xingwu},
  title = {Sitagliptin, a DPP ‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial},
  journal = {Journal of Diabetes},
  year = {2025},
  volume = {17},
  number = {9},
  doi = {10.1111/1753-0407.70156}
}
Kostenlos starten →